Section Arrow
Quote
PCRX.NASDAQ
- Pacira BioSciences
Quotes are at least 15-min delayed:2026/03/04 01:22 EST
Regular Hours
Last
 22.1
+0.82 (+3.85%)
Day High 
22.5 
Prev. Close
21.28 
1-M High
23.73 
Volume 
1.14M 
Bid
15.77
Ask
25.52
Day Low
20.985 
Open
21.07 
1-M Low
20.235 
Market Cap 
874.61M 
Currency 美元 
P/E 45.28 
%Yield -- 
10-SMA 22.79 
20-SMA 21.97 
50-SMA 22.8 
52-W High 27.64 
52-W Low 18.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.47/4.21
Enterprise Value
1.30B
Balance Sheet
Book Value Per Share
17.69
Cash Flow
Cash Flow Yield
0.14
Income Statement
Total Revenue
700.97M
Operating Revenue Per Share
16.20
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health15.82-0.66-4.00%32.25PE
VTRSViatris14.89-0.81-5.16%-- 
TEVATeva Pharmaceutical Industries Limited32.28-1.49-4.41%27.93PE
ESPREsperion Therapeutics2.91-0.365-11.15%-- 
BHCBausch Health Companies5.73-0.22-3.70%14.17PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.